Publications 2009

Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, on behalf of the FHDH ANRS CO4 ANRS CO14. Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients; results from FHDH ANRS CO4. J Acquir Immune Defic Syndr 2009, 50(2):206-14. Lien PubMed

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, and Yéni P, on behalf of the ANRS 127 study group.Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. J Antimicrob Chemother 2009, 64:118-125. Lien PubMed

Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffrédy V, Vittecoq D, Bierling P, Aboulker JP, Molina JM and the ANRS 106 study group.Incidence and Risk Factors of Thrombocytopenia in Patients Receiving Intermittent Antiretroviral Therapy: A Sub-study of the ANRS 106 - Window Trial. JAIDS 2009. Lien PubMed

Ceci A, Giaquinto C, Aboulker JP, Baiardi P, Bonifazi F, Della Pasqua O, Nicolosi A, Taruscio D, Sturkenboom M, Wong I.The Task-force in Europe for Drug Development for the Young (TEDDY) network of excellence. Pediatr Drugs 2009, 11:18-21. Lien PubMed

Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, Gougeon ML, Venet A, Madelaine I, Sereni D, Jeanblanc F, Boulet T, Simon F, Aboulker JP; Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 119 Interstart Study Team.Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). J Infect Dis. 2009, 200:206-15. Lien PubMed

De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM, and the EASIER ANRS 138 study group.Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1-Infected Patients: A Randomized Open-Label Trial. Clin Infect Dis. 2009, 49:1259-67. Lien PubMed 

Altavilla A, Giaquinto C, Giocanti D, Manfredi C, Aboulker JP, Bartoloni F, Cattani E, Lo Giudice M, Mellado Peña, Nagler R, Peterson C, Vajnerova O, Bonifazi F and Ceci A. Activity of ethics committees in Europe on issues related to clinical trials in paediatrics: results of a survey. Pharmaceuticals Policy and Law 2009, 11:79-87.  Lien PubMed  

Larrouy L, Chazallon C, Landman R, Capitant C, Collin, G Storto A, Peytavin G, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D.
Impact of Gag genetic determinants and gag-pol frameshift stability on virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive patients (ANRS 127 trial). Antiviral Ther 2009, 14:A61. Lien PubMed 

Insight-Esprit Study Group, Silcaat Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009, 361:1548-59. Lien PubMed

Descamps D, Chazallon C, Loveday C, et al.Resistance and Virological Response Analyses in a Three Initial Treatment Strategy Trial: A Substudy of the INITIO Trial. HIV Clin Trials 2009, 10:385-393.Lien PubMed